kabutan

ReproCELL Incorporated(4978) Summary

4978
TSE Growth
ReproCELL Incorporated
171
JPY
-1
(-0.58%)
Apr 28, 3:30 pm JST
1.07
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
170
Apr 28, 11:58 pm JST
Summary Chart Historical News Financial Result
PER
PBR
1.85
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
172 JPY 1.07 USD
Previous Close Apr 27
172 JPY 1.07 USD
High Apr 28, 9:08 am
174 JPY 1.09 USD
Low Apr 28, 12:30 pm
171 JPY 1.07 USD
Volume
193,600
Trading Value
0.03B JPY 0.21M USD
VWAP
172.05 JPY 1.08 USD
Minimum Trading Value
17,100 JPY 107 USD
Market Cap
0.02T JPY 0.10B USD
Number of Trades
222
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
Slightly High
1-Year Average
626
1-Year High Jul 2, 2025
8,480
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 0 4,515,200
Apr 17, 2026 0 4,546,200
Apr 10, 2026 0 4,660,100
Apr 3, 2026 0 4,870,500
Mar 27, 2026 0 4,816,300
Company Profile
ReproCELL Incorporated is a biotech venture company specializing in iPS cell-related research reagents, collaborating with the University of Tokyo and Kyoto University. The company also offers contract manufacturing services.
Sector
Chemicals
ReproCELL Incorporated develops businesses centered on iPS cell-related technologies. In its research support division, the company manufactures and sells research products, provides research outsourcing services, and distributes cell measurement equipment. The medical division focuses on regenerative medicine research and development, contract manufacturing of iPS cell regenerative medicine products, and clinical testing services. Currently, ReproCELL is developing three regenerative medicine products: StemCaimal, iPS neural glial cells, and tumor-infiltrating lymphocyte infusion therapy. The company's strength lies in its RNA reprogramming technology, which enables the creation of highly safe iPS cells.